Cargando…

An interim safety analysis of hepatocellular carcinoma patients administrating oral vitamin K with or without sorafenib

BACKGROUNDS/AIMS: Vitamin K may plays a role in controlling hepatocellular carcinoma (HCC) cell growth. In this study, we intended to present 5-year experience of 72 patients receiving oral vitamin K with or without sorafenib. Its end-point was to evaluate the safety of combination therapy using sor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jung, Dong-Hwan, Hwang, Shin, Song, Gi-Won, Ryoo, Baek-Yeol, Kim, Nayoung, Tak, Eunyoung, Hong, Hea-Nam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Association of Hepato-Biliary-Pancreatic Surgery 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494089/ https://www.ncbi.nlm.nih.gov/pubmed/26155269 http://dx.doi.org/10.14701/kjhbps.2015.19.1.1

Ejemplares similares

Synergistic effect of metformin on sorafenib in in vitro study using hepatocellular carcinoma cell lines
por: Chung, Yong-Gyu, et al.
Publicado: (2018)

Absence of antitumor effects of metformin in sorafenib-treated patients with hepatocellular carcinoma recurrence after hepatic resection and liver transplantation
por: Chung, Yong-Kyu, et al.
Publicado: (2018)

Clinical Impact of Vitamin K Dosing on Sorafenib Treatment for Hepatocellular Carcinoma
por: Haruna, Yoshimichi, et al.
Publicado: (2017)

Cytotoxicity of Human Hepatic Intrasinusoidal CD56(bright) Natural Killer Cells against Hepatocellular Carcinoma Cells
por: Hwang, Shin, et al.
Publicado: (2019)

Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells
por: Zhang, Yafei, et al.
Publicado: (2012)

Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma
por: Ha, Yeonjung, et al.
Publicado: (2016)

Differential Response to Sorafenib Administration for Advanced Hepatocellular Carcinoma
por: Huang, Song-Fong, et al.
Publicado: (2022)

Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data
por: Kim, Do Young, et al.
Publicado: (2016)

GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis
por: Lencioni, R, et al.
Publicado: (2014)

Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma
por: Choi, Won‐Mook, et al.
Publicado: (2020)

Efficacy and safety of sorafenib plus vitamin K treatment for hepatocellular carcinoma: A phase II, randomized study
por: Haruna, Yoshimichi, et al.
Publicado: (2021)

High-dose tenofovir is not effective in suppressing hepatitis B virus replication in patients with hepatocellular carcinoma progression: a preliminary result
por: Hwang, Shin, et al.
Publicado: (2016)

Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE)
por: Ryu, Min‐Hee, et al.
Publicado: (2022)

Clinical factors related to long-term administration of sorafenib in patients with hepatocellular carcinoma
por: Nojiri, Shunsuke, et al.
Publicado: (2012)

Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence
por: Kang, Seong Hee, et al.
Publicado: (2018)

Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression
por: Ryoo, Baek-Yeol, et al.
Publicado: (2021)

Upregulation of P2Y2 nucleotide receptor in human hepatocellular carcinoma cells
por: Tak, Eunyoung, et al.
Publicado: (2016)

Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib
por: Oh, Chung Ryul, et al.
Publicado: (2019)

Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study
por: Kaneko, Shuichi, et al.
Publicado: (2016)

Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial
por: Kelley, Robin Kate, et al.
Publicado: (2020)

Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma
por: Ikeda, Atsuyuki, et al.
Publicado: (2021)

Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Mousa, Ali Ben
Publicado: (2008)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Furuse, Junji
Publicado: (2008)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients
por: Teyateeti, Ajalaya, et al.
Publicado: (2020)

Sorafenib with or without concurrent transarterial chemoembolization in hepatocellular carcinoma: a cautionary comment of STAH trial
por: Chen, Jia-Hao, et al.
Publicado: (2020)

Sorafenib Combined with Chemoembolization for Locally Advanced Hepatocellular Carcinoma with Macroscopic Vascular Invasion: A Propensity Score Analysis
por: Kim, Gun Ha, et al.
Publicado: (2021)

The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma
por: Ye, Liangtao, et al.
Publicado: (2019)

Studying the Role and Molecular Mechanisms of MAP4K3 in Sorafenib Resistance of Hepatocellular Carcinoma
por: Shi, Yi, et al.
Publicado: (2020)

Combined Detection of Serum IL-10, IL-17, and CXCL10 Predicts Acute Rejection Following Adult Liver Transplantation
por: Kim, Nayoung, et al.
Publicado: (2016)

Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis
por: Lee, Jung Min, et al.
Publicado: (2016)

Cerebrovascular Accidents Associated with Sorafenib in Hepatocellular Carcinoma
por: Saif, Muhammad W., et al.
Publicado: (2011)

Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma
por: Almhanna, Khaldoun, et al.
Publicado: (2009)

Evolving role of Sorafenib in the management of hepatocellular carcinoma
por: Ziogas, Ioannis A, et al.
Publicado: (2017)

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
por: Ko, Yi-Ling, et al.
Publicado: (2020)

The combination of HTATIP2 expression and microvessel density predicts converse survival of hepatocellular carcinoma with or without sorafenib
por: Wang, Wen-Quan, et al.
Publicado: (2014)

Transarterial chemoembolization with or without sorafenib for hepatocellular carcinoma: A real-world propensity score-matched study
por: Peng, Tzu-Rong, et al.
Publicado: (2021)

Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma
por: Lee, Sangheun, et al.
Publicado: (2013)

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
por: Liu, Qinqin, et al.
Publicado: (2021)

Comparison of stereotactic body radiation therapy with and without sorafenib as treatment for hepatocellular carcinoma with portal vein tumor thrombosis
por: Que, Jenny, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ns6n5kp1b752oedo2vl14vk8qq